stockrowBio-Techne Corp
TECH Healthcare Biotechnology
Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025.
- Revenue
- +1.33%
- EPS
- +418.2%
- Free cash flow
- −6.83%
- Total debt
- −42.2%
Quarter to June 2026, against a year earlier
Follow TECH
Alert me
Bio-Techne Corp (TECH) Return on assets
Bio-Techne Corp's return on assets over the twelve months to 30 June 2026 was 7.07%. Over the past ten years it has ranged from 2.79% (fiscal 2025) to 11.9% (fiscal 2022); the current reading is higher than 50% of that period. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2026 | 7.07% | 4.28 |
| FY2025 | 2.79% | (3.50) |
| FY2024 | 6.29% | (5.27) |
| FY2023 | 11.6% | (0.38) |
| FY2022 | 11.9% | 5.39 |
| FY2021 | 6.55% | (5.17) |
| FY2020 | 11.7% | 6.19 |
| FY2019 | 5.53% | (2.48) |
| FY2018 | 8.01% | 2.35 |
| FY2017 | 5.66% | (3.87) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| TGTX TG Therapeutics, Inc. compare | 37.7% |
| CAI Caris Life Sciences,�Inc. compare | 8.58% |
| TECH Bio-Techne Corp | 7.07% |
| BMRN BioMarin Pharmaceutical Inc. compare | −0.20% |
| TWST Twist Bioscience Corporation compare | −20.8% |
| KYMR Kymera Therapeutics, Inc. compare | −24.4% |
| PCVX Vaxcyte, Inc. compare | −33.0% |
| SMMT Summit Therapeutics PLC compare | −159.1% |
| IBRX ImmunityBio, Inc. compare | −192.6% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on TECH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement